<DOC>
	<DOCNO>NCT01987505</DOCNO>
	<brief_summary>This open-label , single-arm , phase IIIb study evaluate safety switch intravenous ( IV ) subcutaneous ( SC ) administration MabThera/Rituxan first-line treatment patient CD20+ non-Hodgkin 's follicular lymphoma ( FL ) diffuse large B-cell lymphoma ( DLBCL ) already receive least one full dose MabThera/Rituxan IV . Patients FL give 1400 mg MabThera/Rituxan SC induction therapy ( monthly 4-7 cycle ) maintenance therapy ( every 2 month 6-12 cycle ) . 1400 mg SC MabThera/Rituxan give patient DLBCL monthly 4-7 cycle . Treatment duration expect last 7 month patient DLBCL 32 month patient FL .</brief_summary>
	<brief_title>MabRella Study : A Study Evaluate Safety Switching From Intravenous Subcutaneous Administration Mabthera/Rituxan During First-Line Treatment Lymphoma .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age &gt; /= 18 &lt; /= 80 year time enrolment . Life expectancy &gt; /= 6 month . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 3 . Fertile men woman childbearing potential must use effective contraception least 12 month last dose ; woman must pregnant . Histologically confirm CD20+ DLBCL CD20+ follicular NHL ( FL ) grade 1 , 2 3a accord WHO classification system . Induction : Patients FL meet Groupe D'Etude des Lymphomes Folliculaires ( GELF ) criteria initiate treatment . At least tumor &gt; /= 1.5 cm measure compute tomography ( CT ) scan . FL treatmentrelated criterion Currently treat MabThera/Rituxan IV firstline therapy receive least one full dose MabThera/Rituxan IV . Transformed lymphoma . Primary central nervous system lymphoma , primary effusion lymphoma , primary mediastinal DLBCL , DLBCL testis , primary cutaneous DLBCL histologic evidence transformation Burkitt lymphoma . History cancer , include one treated curative intent , unless cancer remission without treatment &gt; /= 5 year prior dose . Note : Patients history cure skin cancer situ carcinoma cervix eligible study . Ongoing corticosteroid use &gt; 30 mg/day prednisone equivalent . Note : patient receive corticosteroid treatment &lt; /= 30 mg/day prednisone equivalent must stable regimen least 4 week prior start dose . Inadequate renal , hematologic , hepatic function . History severe allergic anaphylactic reaction humanize murine monoclonal antibody know sensitivity allergy murine product . For patient DLBCL : Contraindication individual component CHOP ( cyclophosphamide , vincristine , doxorubicin prednisone ) , include prior anthracycline treatment . For patient FL : contraindication standard chemotherapy . Other serious underlie medical condition . Recent major surgery ( within 4 week prior dose ) , diagnosis . Active and/or severe infection ( exclude nail fungal infection ) infection require treatment IV antibiotic hospitalization within 4 week prior dose . Active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . Note : Patients test positive hepatitis B C virus antibody undetectable viral load may include . History human immunodeficiency virus ( HIV ) positive status .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>